tailieunhanh - Báo cáo sinh học: "Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib | Harmon et al. Journal of Translational Medicine 2011 9 120 http content 9 1 120 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib p. u- c I_I s 1c KỲ I IS-. I E H D ri m r 1 9 Cri D í rrvr r I2 A I I I L r z i3 Ct ỉr I I r D r I Iz L c r4 IS-. A f I- IHz-s I ill- . 5 Charles S Harmon Samuel E DePrimo Eric Raymond Ann-Lii Cheng Eveline Boucher Jean-Yves Douillard Ho Y Lim6 Jun S Kim7 Maria José Lechuga8 Silvana Lanzalone8 Xun Lin1 and Sandrine Faivre2 Abstract Background Several proteins that promote angiogenesis are overexpressed in hepatocellular carcinoma HCC and have been implicated in disease pathogenesis. Sunitinib has antiangiogenic activity and is an oral multitargeted inhibitor of vascular endothelial growth factor receptors VEGFRs -l -2 and -3 platelet-derived growth factor receptors PDGFRs -a and -p stem-cell factor receptor KIT and other tyrosine kinases. In a phase II study of sunitinib in advanced HCC we evaluated the plasma pharmacodynamics of five proteins related to the mechanism of action of sunitinib and explored potential correlations with clinical outcome. Methods Patients with advanced HCC received a starting dose of sunitinib 50 mg day administered orally for 4 weeks on treatment followed by 2 weeks off treatment. Plasma samples from 37 patients were obtained at baseline and during treatment and were analyzed for vascular endothelial growth factor VEGF -A VEGF-C soluble VEGFR-2 sVEGFR-2 soluble VEGFR-3 sVEGFR-3 and soluble KIT sKIT . Results At the end of the first sunitinib treatment cycle plasma VEGF-A levels were significantly increased relative to baseline while levels of plasma VEGF-C sVEGFR-2 sVEGFR-3 and sKIT were significantly decreased. Changes from baseline in VEGF-A sVEGFR-2 and sVEGFR-3 but not VEGF-C or sKIT were partially or completely .